These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 27358438)

  • 1. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.
    Haas ME; Levenson AE; Sun X; Liao WH; Rutkowski JM; de Ferranti SD; Schumacher VA; Scherer PE; Salant DJ; Biddinger SB
    Circulation; 2016 Jul; 134(1):61-72. PubMed ID: 27358438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K; Park BS; Kim YW; Vaziri ND
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome.
    Shen H; Feng S; Lu Y; Jiang L; Yang T; Wang Z
    Ren Fail; 2020 Nov; 42(1):405-412. PubMed ID: 32349585
    [No Abstract]   [Full Text] [Related]  

  • 4. Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report.
    Kongmalai T; Chuanchaiyakul N; Srinoulprasert Y; Thongtang N
    J Med Case Rep; 2023 Mar; 17(1):89. PubMed ID: 36899379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Podocytes in Mouse Nephrotic Syndrome.
    Suzuki T; Iyoda M; Kanazawa N; Tachibana S; Honda H
    Lab Invest; 2023 Sep; 103(9):100199. PubMed ID: 37331628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome.
    Molina-Jijon E; Gambut S; Macé C; Avila-Casado C; Clement LC
    Kidney Int; 2020 Dec; 98(6):1449-1460. PubMed ID: 32750454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
    Atreya MR; Whitacre BE; Cvijanovich NZ; Bigham MT; Thomas NJ; Schwarz AJ; Weiss SL; Fitzgerald JC; Allen GL; Lutfi R; Nowak JE; Quasney MW; Shah AS; Wong HR
    Crit Care Med; 2020 Oct; 48(10):1513-1520. PubMed ID: 32769621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
    Lu H; Howatt DA; Balakrishnan A; Graham MJ; Mullick AE; Daugherty A
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1753-7. PubMed ID: 27470509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney-derived PCSK9-a new driver of hyperlipidemia in nephrotic syndrome?
    Artunc F
    Kidney Int; 2020 Dec; 98(6):1393-1395. PubMed ID: 33276863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.
    Liu S; Vaziri ND
    Nephrol Dial Transplant; 2014 Mar; 29(3):538-43. PubMed ID: 24166456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
    Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y
    Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin/kexin type 9 targets megalin in the kidney proximal tubule and aggravates proteinuria in nephrotic syndrome.
    Skeby CK; Hummelgaard S; Gustafsen C; Petrillo F; Frederiksen KP; Olsen D; Kristensen T; Ivarsen P; Madsen P; Christensen EI; Nielsen R; Birn H; Glerup S; Weyer K
    Kidney Int; 2023 Oct; 104(4):754-768. PubMed ID: 37406929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
    Lambert G; Jarnoux AL; Pineau T; Pape O; Chetiveaux M; Laboisse C; Krempf M; Costet P
    Endocrinology; 2006 Oct; 147(10):4985-95. PubMed ID: 16794006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein convertase subtilisin/kexin type 9 biology in nephrotic syndrome: implications for use as therapy.
    Busuioc RM; Covic A; Kanbay M; Banach M; Burlacu A; Mircescu G
    Nephrol Dial Transplant; 2020 Oct; 35(10):1663-1674. PubMed ID: 31157893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9.
    Roche-Molina M; Sanz-Rosa D; Cruz FM; García-Prieto J; López S; Abia R; Muriana FJ; Fuster V; Ibáñez B; Bernal JA
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):50-9. PubMed ID: 25341796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.
    Carreras A; Pane LS; Nitsch R; Madeyski-Bengtson K; Porritt M; Akcakaya P; Taheri-Ghahfarokhi A; Ericson E; Bjursell M; Perez-Alcazar M; Seeliger F; Althage M; Knöll R; Hicks R; Mayr LM; Perkins R; Lindén D; Borén J; Bohlooly-Y M; Maresca M
    BMC Biol; 2019 Jan; 17(1):4. PubMed ID: 30646909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
    Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
    Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.